Vixarelimab has been designed to target oncostatin M receptor beta (OSMRβ) that mediates the interleukin-31 (IL-31) and oncostatin M (OSM) signalling. IL-31 and OSM are two important cytokines
Under the collaboration, the company will partner with the MD Anderson scientists on preclinical trials for further validating TransCode’s RNA-targeted oncology therapy and diagnostic candidates. They will also
Omidubicel is an advanced NAM-enabled stem cell therapy candidate which is being developed as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for blood cancer
The investigational human monoclonal antibody, OMS906 targets mannan-binding lectin-associated serine protease-3 (MASP-3), the main activator of the alternative pathway of the complement system. MASP-3 converts pro-complement factor D
This licence enables the least developed, low-income, lower middle-income as well as Sub-Saharan African countries to access the long-acting HIV prevention medicine. The deal will give the selected
Healthcare venture capital firm Lapam Capital, investment management firm Junson Capital and Dyee Capital have led the financing round. BridGene’s IMTAC platform combines ‘cutting-edge’ technologies including chemical proteomics,
PNI provides technologies, services, and solutions to develop lipid nanoparticle genomic medicines, while Replicate Bioscience designs and delivers srRNA immunotherapies. Under the terms of the deal, PNI will
Tezspire has been recommended as an add-on therapy for these patients whose condition is not sufficiently controlled with high dose inhaled corticosteroids besides another medicinal product for maintenance
The plant-derived small molecule, tigilanol tiglate targets various solid tumours across multiple species. The drug is being developed as an intratumoural treatment for solid tumours. It has a
This study was undertaken in ~184 subjects, who were randomised 1:1 and received either a booster dose of the vaccine or a placebo, ~six months following the primary
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.